Brain Parenchymal Fraction: A Relatively Simple MRI Measure to Clinically Distinguish ALS Phenotypes

Table 2

Demographics and clinical measures of neurologic disease controls and ALS patients.

Clinical measure/ALS subgroups	Neurologic disease controls	ALS-CST+	ALS-CST−	ALS-Cl	ALS-FTD
	15	21	26	23	18
Age (years) (mean ± SD)	57.1 ± 19.2	52.3 ± 11.02	60.1 ± 11.8	58.5 ± 12.6	66.4 ± 9.2
Age range (years)	28–95	32–75	32–76	39–84	52–87
Gender	10 men, 5 women	14 men, 7 women	13 men, 13 women	13 men, 10 women	5 men, 13 women
Duration of symptom prior to MRI (months) (mean ± SD)		9.6 ± 5.5	36.4 ± 44.2	29.1 ± 27.3	37.5 ± 25.2
ALSFRS-R score () (mean ± SD)		34.6 ± 7.8	34.1 ± 8.1	37.2 ± 8.5	30.7 ± 7.1
Disease progression rate (mean ± SD)		1.38 ± 1.64	0.46 ± 0.43	0.68 ± 0.77	0.59 ± 0.33